PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26893664-8 2016 Naringenin and ABT-737 also decreased Akt activation and increased p53 expression, suggesting the involvement of these pathways in the inhibition of gastric cell growth. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 15-18 tumor protein p53 Homo sapiens 67-70 25548100-7 2015 Concurrent Bcl-xL antagonism by the BH3 mimetic ABT-263 combined with carfilzomib synergistically enhanced apoptosis that was dependent on Bax or p53, and was attenuated by Noxa or Bik shRNA. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 48-51 tumor protein p53 Homo sapiens 146-149 25181509-6 2014 When MI-63 was combined with the BH3 mimetic ABT-737, enhanced activity was seen in both wild-type and mutant p53 models. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 45-48 tumor protein p53 Homo sapiens 110-113 22002102-6 2012 Wild type p53 function inhibits the efficacy of a combined IR and ABT-737 treatment via a p21-dependent G1 cell cycle arrest. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 66-69 tumor protein p53 Homo sapiens 10-13 22002102-7 2012 Moreover, mutant as well as wild type p53 counteract the pro-apoptotic activity of ABT-737 by maintaining the expression levels of the Mcl-1 protein. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 83-86 tumor protein p53 Homo sapiens 38-41 22002102-8 2012 Thus, p53 regulates the sensitivity to ABT-737 of glioblastoma cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 39-42 tumor protein p53 Homo sapiens 6-9 22759956-5 2012 Adenosine upregulated expression of the p53 mRNA and protein, that is abolished by ABT-702, but not by knocking-down A(3) adenosine receptor. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 83-86 tumor protein p53 Homo sapiens 40-43 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 114-117 tumor protein p53 Homo sapiens 196-199 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 114-117 tumor protein p53 Homo sapiens 222-225 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 114-117 tumor protein p53 Homo sapiens 222-225 30367486-1 2019 The objective was to investigate the upstream mechanisms of apoptosis which were triggered by a novel antimicrotubule drug, ABT-751, in a tumor protein p53 ( TP53)-deficient hepatocellular carcinoma-derived Hep-3B cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 124-127 tumor protein p53 Homo sapiens 152-155 30367486-1 2019 The objective was to investigate the upstream mechanisms of apoptosis which were triggered by a novel antimicrotubule drug, ABT-751, in a tumor protein p53 ( TP53)-deficient hepatocellular carcinoma-derived Hep-3B cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 124-127 tumor protein p53 Homo sapiens 158-162 30367486-7 2019 Pharmacological inhibition of autophagosome (early autophagy) but not autolysosome (late autophagy) enhanced ABT-751-induced apoptosis in TP53-deficient Hep-3B cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 109-112 tumor protein p53 Homo sapiens 138-142 30367486-8 2019 Our study provided a new strategy to augment ABT-751-induced apoptosis in TP53-deficient cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 45-48 tumor protein p53 Homo sapiens 74-78 28843007-6 2018 Western blot analysis indicated that ABT-737 combined with HQ increased the levels of cleaved PARP and gamma-H2AX, but significantly decreased the level of P53. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 37-40 tumor protein p53 Homo sapiens 156-159 26996126-0 2016 Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 156-159 tumor protein p53 Homo sapiens 167-170 26996126-7 2016 From this result, we tested the effect of ABT-263 (Navitoclax), the specific inhibitor of Bcl-2 and Bcl-XL, but not Mcl-1, and found that ABT-263 synergistically enhanced cisplatin-induced apoptosis in NSCLC cells in the presence or absence of p53. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 138-141 tumor protein p53 Homo sapiens 244-247 26704388-11 2016 A role for p53 appears important as GCS-100 induces p53 expression and shRNA knockdown of p53 protected OCI-AML3 cells from the cytotoxic effects of the GCS-100/ABT-737 treatment combination. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 161-164 tumor protein p53 Homo sapiens 11-14 26704388-11 2016 A role for p53 appears important as GCS-100 induces p53 expression and shRNA knockdown of p53 protected OCI-AML3 cells from the cytotoxic effects of the GCS-100/ABT-737 treatment combination. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 161-164 tumor protein p53 Homo sapiens 52-55 26704388-11 2016 A role for p53 appears important as GCS-100 induces p53 expression and shRNA knockdown of p53 protected OCI-AML3 cells from the cytotoxic effects of the GCS-100/ABT-737 treatment combination. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 161-164 tumor protein p53 Homo sapiens 52-55 22875003-3 2012 We have profiled ABT-737 specificity for all six pro-survival Bcl-2 proteins, in p53 wild-type or p53-mutant human T-leukemic cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 tumor protein p53 Homo sapiens 81-84 22875003-3 2012 We have profiled ABT-737 specificity for all six pro-survival Bcl-2 proteins, in p53 wild-type or p53-mutant human T-leukemic cells. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 17-20 tumor protein p53 Homo sapiens 98-101 21398407-4 2011 Moreover, these synergistic effects of vorinostat/ABT-737 were blunted in cells with an inactive p53 pathway or in cells lacking expression of the p53 target gene, noxa. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 50-53 tumor protein p53 Homo sapiens 97-100 21398407-4 2011 Moreover, these synergistic effects of vorinostat/ABT-737 were blunted in cells with an inactive p53 pathway or in cells lacking expression of the p53 target gene, noxa. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 50-53 tumor protein p53 Homo sapiens 147-150 21084274-9 2011 By overexpression of a dominant-negative p53 protein, we show that ABT-737-induced cellular senescence is p53-dependent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 67-70 tumor protein p53 Homo sapiens 41-44 21084274-9 2011 By overexpression of a dominant-negative p53 protein, we show that ABT-737-induced cellular senescence is p53-dependent. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 67-70 tumor protein p53 Homo sapiens 106-109